Global Tularemia Infection Market

Global Tularemia Infection Market By Type (Ulceroglandular, Typhoidal, Oculoglandular and Others), Treatment (Medication, Vaccinations, Surgery), Drugs (Aminoglycosides, Quinolones and Others), Vaccine (Live Attenuated Vaccines, Acellular Subunit and Others), Route of Administration (Oral, Injectable), End- Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Others), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) - Industry Trends and Forecast to 2026

Market Analysis: Global Tularemia Infection Market 

Global tularemia Infection market is expected to grow at a substantial CAGR in the forecast period of 2019-2026. Emergence of drugs used to treat risk associated with tularemia Infection and high demand of disease specific novel therapies are the key factors that fueling the market growth

Market Definition: Global Tularemia Infection Market 

Tularemia is also known as deerfly fever or rabbit fever is an infectious disease caused by the gram-negative bacteria francisella tularensis that infects wild rodents, squirrels, birds, rabbit and can infect the human by direct contact with an infected animal or from tick, mosquito, or deer fly bites. It can cause a severe flu-like illness and long-term health problems.

According to the statistics published in the National Organization for Rare Disorders, Inc. an estimated annual incidence of tularemia is approximately 100-200 case in the United States. Growing special designation from the regulatory authorities for treatment of tularemia infection is fueling market growth.

Market Drivers

• Increase in number of farmers, especially those who work with animals, people who are engaged in slaughterhouses and veterinary personnel are vulnerable to this disease is boosting the market growth
• High demand of disease specific novel treatment can also act as a market driver
• Huge financial support to the researchers for developing novel intervention is boosting the market growth
• Emergence of drugs used in the treatment of symptoms associated with Q-fever is enhancing the market

Market Restraints

• Limited operating revenue opportunities for research and development of targeted therapies by many pharmaceuticals is acting as a challenging factor for the growth of this market
• Low healthcare budget in some developing countries is hamper the market growth

Segmentation: Global Tularemia Infection Market 

By Type

• Ulceroglandular
• Typhoidal
• Oculoglandular
• Others

By Treatment

• Medication
• Vaccinations
• Surgery

By Drugs

• Aminoglycosides
  • Streptomycin
  • Gentamicin
• Quinolones
  • Ciprofloxacin
  • Levofloxacin
• Others

By Vaccine

• Live attenuated vaccines
• Acellular subunit
• Others

By Route of Administration

• Oral
• Injectable

 By End Users

• Hospitals
• Homecare
• Specialty Clinics
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Others

By Geography

• North America
  • U.S.
  • Canada
  • Mexico
• South America
  • Brazil
  • Rest of South America
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Turkey
  • Belgium
  • Netherlands
  • Switzerland
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • South Korea
  • India
  • Australia
  • Singapore
  • Thailand
  • Malaysia
  • Indonesia
  • Philippines
  • Rest of Asia Pacific
• Middle East & Africa
  • South Africa
  • Rest of Middle East & Africa

Key Developments in the Market:

In January 2018, Appili Therapeutics entered into a license agreement with National Research Council of Canada (NRC) to develop ATI-1701, a vaccine to protect against Francisella tularensis. This alliance represents the advancement in the treatment to protect the health of Canadians suffering from tularemia.

In September 2015, Tetraphase Pharmaceuticals received Qualified Infectious Disease Product (QIDP) and Fast Track designations from the FDA for the intravenous formulation of TP-271, a novel, broad spectrum antibiotic candidate for the treatment of infections including Francisella tularensis, Yersinia pestis and Bacillus anthracis. The special designations of TP-271 provide significant support for the development of new antibiotic treatments for serious and potentially life-threatening infections.

Competitive Analysis:

Global tularemia Infection market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of global tularemia Infection market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Key Market Players:

Few of the major competitors currently working in the global tularemia Infection market are Appili Therapeutics, Tetraphase Pharmaceuticals, Merck & Co., Inc, Aradigm Corporation, Debiopharm Group, EpiVax, Inc., Cerus Corporation, Aduro Biotech, Emergent BioSolutions Inc, DEINOVE,  Sun Pharmaceutical Industries Ltd, Fresenius Kabi AG, Teva Pharmaceutical Industries Ltd, Novartis AG, Pfizer Inc and others